Table 2. Change from baseline in hospital anxiety and depression scale scores and visual analog scale scores at the recall visit for patients treated with poly-L-lactic acid for human immunodeficiency virus-associated facial lipoatrophy in a clinical study [20]

 

 

Immediate Group (n=13)

Delayed Group (n=14)

 

Baseline

Recall Visit

Baseline

Recall Visit

Anxiety score

7.9

7.2

10.3

7.9

Depression score

5.1

4.8

7.3

3.8

Visual analog scale score*

2.5

5.8

1.4

5.5

*P<0.05 between groups for mean change from baseline at recall visit (paired test).

 

Adapted with permission from Moyle GJ et al, Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy, HIV Med. 2006; 7:181-185 [20].